JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.

Suppr

超能文献

作者信息

Regina S, Herault O, D'Alteroche L, Binet C, Gruel Y

出版信息

J Thromb Haemost. 2007 Apr;5(4):859-61. doi: 10.1111/j.1538-7836.2007.02384.x.

DOI:10.1111/j.1538-7836.2007.02384.x

PMID:17403204

Abstract

摘要

相似文献

JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis.

J Thromb Haemost. 2007 Apr;5(4):859-61. doi: 10.1111/j.1538-7836.2007.02384.x.

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.

J Thromb Haemost. 2007 Apr;5(4):708-14. doi: 10.1111/j.1538-7836.2007.02424.x. Epub 2007 Jan 29.

The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.

Pathol Oncol Res. 2016 Jan;22(1):229-30. doi: 10.1007/s12253-015-9994-8. Epub 2015 Oct 8.

Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.

Thromb Res. 2013 Aug;132(2):e99-e104. doi: 10.1016/j.thromres.2013.07.014. Epub 2013 Aug 1.

CALR exon 9 mutations in idiopathic splanchnic vein thrombosis in an Australian cohort.

Thromb Res. 2017 Feb;150:51-52. doi: 10.1016/j.thromres.2016.12.010. Epub 2016 Dec 15.

JAK2 mutations across a spectrum of venous thrombosis cases.

Am J Clin Pathol. 2010 Jul;134(1):82-5. doi: 10.1309/AJCP7VO4HAIZYATP.

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?

Cerebrovasc Dis. 2017;44(3-4):97-104. doi: 10.1159/000471891. Epub 2017 Jun 14.

Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.

J Hepatol. 2021 Jan;74(1):89-95. doi: 10.1016/j.jhep.2020.06.045. Epub 2020 Jul 15.

The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis.

Blood. 2011 Apr 14;117(15):3968-73. doi: 10.1182/blood-2010-11-319087. Epub 2011 Mar 1.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

引用本文的文献

Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review.

Medicina (Kaunas). 2025 May 21;61(5):933. doi: 10.3390/medicina61050933.

JAK2V617F Mutation in Patient with Splanchnic Vein Thrombosis.

Indian J Hematol Blood Transfus. 2020 Oct;36(4):700-704. doi: 10.1007/s12288-020-01292-x. Epub 2020 May 25.

The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease.

Inflamm Bowel Dis. 2021 Jan 19;27(2):215-223. doi: 10.1093/ibd/izaa053.

JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis.

Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):4-8. doi: 10.1007/s12288-012-0215-2. Epub 2012 Dec 18.

Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?

Can J Gastroenterol Hepatol. 2014 Apr;28(4):207-11. doi: 10.1155/2014/353672.

The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.

J Thromb Thrombolysis. 2012 Oct;34(3):388-96. doi: 10.1007/s11239-012-0738-2.

Venous thromboembolic disease.

J Natl Compr Canc Netw. 2011 Jul 1;9(7):714-77. doi: 10.6004/jnccn.2011.0062.

Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.

Ann Hematol. 2012 Jan;91(1):103-7. doi: 10.1007/s00277-011-1233-0. Epub 2011 Apr 12.

JAK2V617F mutation in patients with splanchnic vein thrombosis.

Dig Dis Sci. 2010 Jun;55(6):1770-7. doi: 10.1007/s10620-009-0933-y. Epub 2009 Aug 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验